ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
The FDA has issued a CRL to Saol Therapeutics regarding the NDA for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback